v3.25.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating expenses:    
Research and development $ 20,258 $ 11,376
General and administrative 5,973 6,141
Total operating expenses 26,231 17,517
Loss from operations (26,231) (17,517)
Other income, net 3,261 4,206
Net loss $ (22,970) $ (13,311)
Net loss per share, basic (usd per share) $ (0.89) $ (0.55)
Net loss per share, diluted (usd per share) $ (0.89) $ (0.55)
Weighted-average, common shares outstanding, basic (in shares) 25,692 24,082
Weighted-average, common shares outstanding, diluted (in shares) 25,692 24,082
Other comprehensive loss:    
Unrealized loss on investments $ (69) $ (320)
Comprehensive loss $ (23,039) $ (13,631)